Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-081 in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
NCT04036682Phase 2Active, not recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- Oct 2019
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of zipalertinib in non-small cell lung cancer (NSCLC), sponsored by Cullinan Therapeutics. Started Oct 2019; status: active, not recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04036682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036682.